Baclofen-based Solutions for Environmental Sustainability
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of stable oral suspensions of baclofen to develop novel applications in environmental sustainability, including treating aquatic life, reducing algae growth, enhancing bioremediation, improving soil quality, and reducing pesticide use in agriculture.
Background and Problem Solved
The original patent focused on stable oral suspensions of baclofen for human pharmaceutical use, but the limitations of the patent did not explore the potential of baclofen in environmental sustainability. This inventive concept addresses the need for innovative solutions in environmental conservation, specifically in aquatic ecosystems, soil quality, and bioremediation.
Detailed Description of the Inventive Concept
The inventive concept involves applying the stable oral suspension of baclofen to various environmental applications. In aquatic life treatment, the suspension reduces stress and anxiety in aquatic organisms. In algae growth reduction, the baclofen inhibits algae growth in aquatic environments. In bioremediation, the suspension enhances the degradation of pollutants. In soil quality improvement, the suspension increases the growth of beneficial microorganisms. Finally, in reducing pesticide use, the suspension increases the natural resistance of crops to pests. The common thread among these applications is the use of baclofen as a key component, leveraging its therapeutic properties to achieve environmental benefits.
Novelty and Inventive Step
The new claims introduce a paradigm shift in the application of baclofen, moving from human pharmaceutical use to environmental sustainability. The inventive concept combines the core technology of stable oral suspensions of baclofen with novel environmental applications, resulting in a non-obvious and innovative solution.
Alternative Embodiments and Variations
Alternative embodiments could include using different concentrations of baclofen, varying the pH range of the suspension, or incorporating additional components to enhance the environmental benefits. Variations could also involve applying the inventive concept to other environmental areas, such as air pollution remediation or waste management.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the environmental sustainability market, with potential applications in aquatic ecosystems, agriculture, and bioremediation. The market for environmental sustainability solutions is growing rapidly, driven by increasing concerns about climate change and ecosystem degradation. The inventive concept could be licensed to companies operating in these industries, providing a new revenue stream for ANI Pharmaceuticals, Inc.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations and environmental applications, with expertise in drug suspension technologies, pharmacological compound manipulation, and environmental treatment methods
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, chemistry, or environmental engineering, possessing knowledge of drug formulation techniques, suspension stability, and interdisciplinary applications of pharmaceutical compounds
Obviousness Rationale
A PHOSITA would recognize that the stable oral suspension technology of baclofen disclosed in the source patent provides a versatile platform for exploring alternative applications beyond human pharmaceutical use. The fundamental properties of the baclofen suspension - stability, controlled concentration, and adaptable pH range - inherently suggest potential for broader environmental interventions. The PTD's environmental applications represent predictable extensions of the core suspension technology by leveraging known pharmacological properties of baclofen in novel contextual domains.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,524 |
|---|---|
| Title | Stable oral suspensions of baclofen |
| Assignee(s) | ANI Pharmaceuticals, Inc. |